OncoGenex Pharmaceuticals

Type: Company
Name: OncoGenex Pharmaceuticals
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

OncoGenex Pharmaceuticals : Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

By a News Reporter-Staff News Editor at Biotech Week -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per ... [Published 4 Traders - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

4 Under-$10 Biotech Stocks in Breakout Territory

aDELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers. Read More: Warren Buffett's Top 10 Dividend StocksStocks that are making large moves like these ... [Published The Street Latest - Aug 27 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

OncoGenex Pharmaceuticals appoints vice president and CFO

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has appointed John Bencich as vice president and CFO. John will lead the company's financial and administrative operations, reporting directly to OncoGenex President and CEO Scott Cormack."John ... [Published Individual.com - Aug 23 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 8 reports

OncoGenex's Custirsen Passes First Interim Futility Analysis…

OncoGenex Pharmaceuticals, Inc. ( OGXI - Snapshot Report ) announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of the randomized, open-label phase III ENSPIRIT study on custirsen for the treatment of advanced ... [Published Zacks.com - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

OncoGenex Says Lung Cancer Drug Trial Will Continue

OncoGenex Pharmaceuticals Inc. Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "OncoGenex Says Lung Cancer Drug Trial Will Continue"Search BioPortfolio ... [Published BioPortfolio - Aug 22 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 3 reports

OncoGenex Pharmaceuticals CMO Cindy Jacobs Unloads 5,650 Shares (OGXI)

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CMO Cindy Jacobs unloaded 5,650 shares of OncoGenex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $3.17, for a total transaction of $17,910.50. ... [Published American Banking News - Forex - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q2 2014 Results - Earnings Call Transcript

OperatorGood afternoon, ladies and gentlemen, and welcome to the OncoGenex Second Quarter 2014 Earnings Conference Call. My name is Sam, and I will be the operator for today's call. [Operator Instructions] At this time, I would like to turn the call over ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

OncoGenex Pharmaceuticals Releases 2Q Financial Results

OncoGenex Pharmaceuticals provided a summary of clinical developments and reported second quarter 2014 financial results. In its release on Aug. 7, the Company said:-Revenue for the three and six months ended June 30, was $4.9 million and $16.7 million, ... [Published Individual.com - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer

OncoGenex Pharmaceuticals, Inc. has appointed  John A. Bencich  as vice president and chief financial officer (CFO).  John Bencich , an experienced life sciences and technology industry executive, is joining the company effective  August 11 2014 . John ... [Published PharmaAsia - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

OncoGenex Q2 Loss Narrower than Expected, Revenues Down Y/Y

OncoGenex Pharmaceuticals, Inc. ( OGXI - Snapshot Report ) reported a loss of 47 cents per share, narrower than the year-ago loss of 57 cents as well as the Zacks Consensus Estimate of a loss of 49 cents.Second-quarter revenues decreased 22.3% year ... [Published Zacks.com - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 4 reports

OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 8.2%

OncoGenex Pharmaceuticals, Inc. ( OGXI ) was a big mover last session, as its shares rose over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, ... [Published Yahoo! Finance - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 4 reports

OncoGenex Pharmaceuticals elects John A. Bencich as VP and CFO

Biopharmaceutical company OncoGenex Pharmaceuticals (NasdaqCM:OGXI) Thursday named John A. Bencich as its vice president and chief financial officer. Effective 11 August 2014, Bencich will lead the company's financial and administrative operations, reporting ... [Published Individual.com - Aug 07 2014]

Quotes

...we are very pleased that ENSPIRIT has passed this important early interim futility analysis," said Scott Cormack , President and CEO of OncoGenex. "We remain strong in our belief that targeting mechanisms of treatment resistance is a critical path forward in the fight against cancer and we continue to actively pursue this approach through the two ongoing Phase 3 trials of custirsen and the seven Phase 2 trials of apatorsen in four tumor types."
...corporate growth expertise that will be invaluable as we shape the future of OncoGenex," said Scott Cormack, President and CEO of OncoGenex. "The Board of Directors joins me in welcoming John to his new position and we look forward to his substantial contributions to drive OncoGenex' future success."
...Second, there has been no word on the next steps toward approval, other than chief operating officer Julie Smith's  statement:   "We plan to meet with regulators soon for the purpose of defining the next step toward the potential approval of RP103 for Huntington's disease in the U S and Europe."

More Content

All (74) | News (54) | Reports (0) | Blogs (17) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
OncoGenex Pharmaceuticals : Announces Update on... [Published 4 Traders - Aug 28 2014]
4 Under-$10 Biotech Stocks in Breakout Territory [Published The Street Latest - Aug 27 2014]
OncoGenex Pharmaceuticals appoints vice preside... [Published Individual.com - Aug 23 2014]
OncoGenex's Custirsen Passes First Interim Futi... [Published Zacks.com - Aug 22 2014]
OncoGenex's Custirsen Passes First Interim Futi... [Published Yahoo! Finance - Aug 22 2014]
Sector Update: Health Care Stocks Mixed; OncoGe... [Published Nasdaq - Aug 22 2014]
OncoGenex Says Lung Cancer Drug Trial Will Cont... [Published BioPortfolio - Aug 22 2014]
OncoGenex Phase 3 ENSPIRIT Trial Continuing As ... [Published FinanzNachrichten.de - Aug 22 2014]
OncoGenex Pharmaceuticals Inc announces update ... [Published Reuters - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published Benzinga.com - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published Barchart - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
OncoGenex Pharmaceuticals CMO Cindy Jacobs Unlo... [Published American Banking News - Forex - Aug 15 2014]
OncoGenex Pharmaceuticals CMO Sells $17,911 in ... [Published American Banking News - Aug 15 2014]
OncoGenex Pharmaceuticals CEO Unloads $58,141 i... [Published American Banking News - Forex - Aug 15 2014]
Why Raptor Is Down, Despite Possibility of New ... [Published TheStreet.com - Aug 14 2014]
Why Raptor Is Down, Despite Possibility of New ... [Published The Street Latest - Aug 14 2014]
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cor... [Published Seeking Alpha - Aug 13 2014]
OncoGenex Pharmaceuticals Releases 2Q Financial... [Published Individual.com - Aug 12 2014]
OncoGenex Pharmaceuticals Announces Appointment... [Published PharmaAsia - Aug 11 2014]
OncoGenex Q2 Loss Narrower than Expected, Reven... [Published Zacks.com - Aug 08 2014]
Ex-Sanofi exec Whitaker takes the reins at Synta [Published FierceBiotech - Aug 08 2014]
Frontrunning: August 8 [Published Zero Hedge - Aug 08 2014]
4 Stocks Under $10 Making Big Moves [Published The Street Latest - Aug 08 2014]
OncoGenex Pharmaceuticals (OGXI) Soars: Stock U... [Published Yahoo! Finance - Aug 08 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Nasdaq - Aug 07 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
OncoGenex Pharmaceutical Up 11.6%, Shares Break... [Published Individual.com - Aug 07 2014]
OncoGenex Pharmaceuticals elects John A. Bencic... [Published Individual.com - Aug 07 2014]
OncoGenex Pharmaceuticals Announces Appointment... [Published Bio-Medicine - Aug 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), ...
Frontrunning: August 8 [Published Zero Hedge - Aug 08 2014]
Pope Francis calls for action as Iraqi Christians forced to flee ( Reuters ) Richest Russians Deprived of Luxury Foods by Putin’s Ban ( BBG ) Exxon Drilling Russian Arctic Shows Sanction Lack Bite ( BBG ) Israeli Jets Strike Gaza Targets After Rockets ...
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results.Clinical Developments and ...
OncoGenex Pharmaceuticals Announces Appointment... [Published PR Newswire: General Business - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).  John Bencich, an experienced ...
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 24, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2014 financial results will be released on Thursday, August 7, 2014, and that ...
1 2 3 4

Press Releases

sort by: Date | Relevance
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Apr 30 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Mar 11 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.